News & Updates

6-month single antiplatelet regimen after DAPT post-PCI may reduce GI injury

25 Nov 2021 by

Among patients who received 6 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), switching to a single antiplatelet therapy (SAPT) regimen for another 6 months resulted in less gastrointestinal (GI) injury than continuing DAPT, results of the OPT-PEACE trial showed.

6-month single antiplatelet regimen after DAPT post-PCI may reduce GI injury

25 Nov 2021

Dupilumab benefits in EoE sustained through 52 weeks

23 Nov 2021 by

The anti–interleukin (IL)-4/-13 antibody dupilumab led to sustained improvements across symptomatic, histologic, and endoscopic measures of eosinophilic oesophagitis (EoE) out to 52 weeks, according to additional data from the LIBERTY EoE TREET trial presented at ACG 2021.

Dupilumab benefits in EoE sustained through 52 weeks

23 Nov 2021

High-dose corticosteroid good for maintenance treatment in eosinophilic esophagitis

23 Nov 2021 by

Eosinophilic esophagitis patients are likely to experience histological relapse despite ongoing treatment with swallowed topical corticosteroid (STC), but relapse occurs later with high- than with low-dose STC without any increase in side effects, a study has found.

High-dose corticosteroid good for maintenance treatment in eosinophilic esophagitis

23 Nov 2021

Obesity ups risk of early-onset colorectal cancer

22 Nov 2021 by

Obese people are more likely to develop early-onset colorectal cancer (CRC), suggests a study, noting that the increasing prevalence of obesity in younger generations may significantly contribute to the increase in this disease.

Obesity ups risk of early-onset colorectal cancer

22 Nov 2021

Ornithine phenylacetate no better than placebo for cirrhosis, hepatic encephalopathy

20 Nov 2021

In the treatment of patients with cirrhosis and hepatic encephalopathy (HE), the ammonia scavenger ornithine phenylacetate is safe and similar to placebo in terms of time to clinical improvement, according to data from a phase IIb trial.

Ornithine phenylacetate no better than placebo for cirrhosis, hepatic encephalopathy

20 Nov 2021

Energy-restricted Mediterranean diet plus physical activity improves HDL function

19 Nov 2021

An energy-restricted Mediterranean diet combined with physical activity (PA) results in better high-density lipoprotein (HDL) triglyceride metabolism compared with a nonrestrictive diet without PA in older adults with metabolic syndrome (MetS), reports a study.

Energy-restricted Mediterranean diet plus physical activity improves HDL function

19 Nov 2021

Vonoprazan trumps PPI in ridding off H. pylori

18 Nov 2021 by

Vonoprazan-containing triple- or dual-therapy regimens are superior to lansoprazole triple therapy in eradicating Helicobacter pylori (H. pylori), according to the phase III pHalcon-HP study presented at ACG 2021.

Vonoprazan trumps PPI in ridding off H. pylori

18 Nov 2021

Overeating ups risk of digestive system cancers

18 Nov 2021

People with unrestrained eating behaviour are at higher risk of gastrointestinal (GI) tract cancers, reveals a recent study.

Overeating ups risk of digestive system cancers

18 Nov 2021

Long-term TAF works against resistant HBV, poses no excess cardiovascular risk

17 Nov 2021 by

Tenofovir alafenamide (TAF) shows sustained safety and efficacy in heavily pretreated patients with multidrug-resistant hepatitis B virus (HBV) through 3 years of treatment, albeit leading to elevations in cholesterol levels.

Long-term TAF works against resistant HBV, poses no excess cardiovascular risk

17 Nov 2021

Statins reduce hepatocellular carcinoma risk in cirrhotic patients

17 Nov 2021

The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.

Statins reduce hepatocellular carcinoma risk in cirrhotic patients

17 Nov 2021

News & Updates

Filter by Specialty:

Specialty:

6-month single antiplatelet regimen after DAPT post-PCI may reduce GI injury

6-month single antiplatelet regimen after DAPT post-PCI may reduce GI injury

Dupilumab benefits in EoE sustained through 52 weeks

Dupilumab benefits in EoE sustained through 52 weeks

High-dose corticosteroid good for maintenance treatment in eosinophilic esophagitis

High-dose corticosteroid good for maintenance treatment in eosinophilic esophagitis

Obesity ups risk of early-onset colorectal cancer

Obesity ups risk of early-onset colorectal cancer

Ornithine phenylacetate no better than placebo for cirrhosis, hepatic encephalopathy

Ornithine phenylacetate no better than placebo for cirrhosis, hepatic encephalopathy

Energy-restricted Mediterranean diet plus physical activity improves HDL function

Energy-restricted Mediterranean diet plus physical activity improves HDL function

Vonoprazan trumps PPI in ridding off H. pylori

Vonoprazan trumps PPI in ridding off H. pylori

Overeating ups risk of digestive system cancers

Overeating ups risk of digestive system cancers

Long-term TAF works against resistant HBV, poses no excess cardiovascular risk

Long-term TAF works against resistant HBV, poses no excess cardiovascular risk

Statins reduce hepatocellular carcinoma risk in cirrhotic patients

Statins reduce hepatocellular carcinoma risk in cirrhotic patients